BRD9 and acute myeloid leukemia: To assess the clinical potential of BRD9 targeting for AML, we investigated the antileukemic activity of QA-68 and EA-89 against primary AML cells (patient details provided in Supplementary Table 1), using proliferation and colony formation assays (Fig. 5).